Glenmark Life Sciences (GLS), the active pharmaceutical ingredient (API) spin off from Glenmark Pharma has announced its initial public form (IPO).
The IPO of Glenmark Life Sciences will open on Tuesday, 27 July 2021 and will end on Thursday, 29 July 2021.
The company aims to raise Rs 15 bn at the lower band of offer price and Rs 15.1 bn at the upper band.
The price band for the Glenmark Life Sciences IPO has been fixed between Rs 695 and Rs 720 per share.
Kotak Mahindra Capital, BofA Securities India, and Goldman Sachs (India) are the global co-ordinators and book running lead managers to the offer.
DAM Capital Advisors, BOB Capital Markets, and SBI Capital Markets are the book running lead managers to the offer.
| Issue Type | Book Built Issue IPO |
| Face Value | Rs 2 per equity share |
| IPO Price | Rs 695 to Rs 720 per equity share |
| Market Lot | 1 lot - 20 shares |
| Issue Size | Rs 15.1 bn |
| Fresh Issue | Rs 10.6 bn |
| Offer for Sale | Rs 4.5 bn |
| Basis of Allotment Date | Tuesday, August 3, 2021 |
| IPO Listing Date | Friday, August 6, 2021 |
The promoter for the company in the upcoming IPO is Glenmark Pharmaceuticals and it holds a pre-IPO share of 100%.
The post IPO shareholdings for the same is expected to be around 82.8%.
The promoter group as per the draft red herring prospectus (DRHP) outlines Glenn Saldanha and Cherylann Pinto as the main shareholders going forward. Glenn Saldanha is the chairman and non-executive director of the company.
--- Advertisement ---
This is a Powerful Mega Trend Playing Out in India
We have uncovered a powerful mega trend that is playing out in India right now.
It could potentially generate immense wealth for early movers.
Our co-head of research Tanushree Banerjee has also zeroed in on one specific stock riding this mega trend.
It's her #1 stock pick right now.
And she believes, this could be one of the top stocks to get to potential Rs 7 crore wealth over the long term.
Tanushree will reveal all the details about this mega trend and her #1 stock at her special online event on July 29.
At the event Tanushree will also show you, how to potentially accumulate Rs 7 crore in wealth over the long term.
What you learn at the event could possibly change your financial fortunes forever.
Click here to reserve your FREE seat.
------------------------------
The qualified institutional buyers (QIBs) have an investor portion of 50% of the offer reserved for them.
The non-institutional buyers on the other hand have a 15% allocation reserved, while individual retail bidders have a 35% allocation for this IPO.
The company plans to use the proceeds from the public issue for the payment of outstanding purchase considerations to the promoter for the spin-off of the API business from the promoter and into the company.
It also aims to use it to fund capital expenditure requirements as well as general corporate purposes.
Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of active pharmaceutical ingredients (APIs).
The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.
It further operates in contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.
Its products are being sold in India and also exported to multiple countries such as Europe, North America, Latin America, Japan, etc.
Currently, it has 4 manufacturing facilities at Ankleshwar & Dahej in Gujarat and Mohol & Kurkumbh in Maharashtra with an aggregate annual installed capacity of 725.8 KL as of 31 December 2020.
Free Signup: The Smallcap Revival Summit
The company is a leading manufacturer of specialised APIs that are specifically used for chronic therapeutic areas like cardiovascular disease (CVS), central nervous system disease (CNS), diabetes, and pain management.
It also has strong international ties with big pharma companies and exports globally.
The company also has a high-quality standard of product manufacturing with research and development (R&D) infrastructure according to reports.
Added to this, it has a proven financial track record that has improved over the years, and it makes for a strong front-runner.
The company has posted growth in its top and bottom lines for the last three fiscals.
For the financial year of 2021, Glenmark Life reported a profit of Rs 3.5 bn as well as a revenue of Rs 18.9 bn for the same year.
In the previous financial of 2020, it had a lower profit margin of Rs 3.1 bn upon the revenue of Rs 15.4 bn.
This marks an upward trend in profits and revenue with the latest financial year marking the highest in returns.
| (Rs bn) | FY19 | FY20 | Dec-20 |
|---|---|---|---|
| Revenues | 8.9 | 15.4 | 14.2 |
| Revenue Growth (%) | 73% | ||
| Expenses | 6.6 | 11.3 | 10.9 |
| Profit Before Tax (PBT) | 2.3 | 4.2 | 3.3 |
| Net Profit | 2 | 3.1 | 2.5 |
The company has not declared or paid any dividend during the three immediately preceding financial years and until the date of filing of this red herring prospectus.
GLS will adopt a prudent dividend policy post listing based on its financial performance and future prospects.
For more details, check out Glenmark Life's Red Herring Prospectus.
--- Advertisement ---
How Fund Managers Spot Winning Stocks
Fund managers don't buy stocks on a whim. They buy only when they can get the best price in the market.
By using Wyckoff Accumulation Analysis, you can get the same edge as fund managers.
Watch this video to learn how to spot winning stocks like fund managers.
------------------------------
As per the offer documents, Glenmark Life Sciences has shown Divis Lab, Laurus Labs, Shilpa Medicare, Aarti Drugs, and Solara Active Pharma as its listed peers.
| Company | Revenues | Net Profit | Return on NetWorth (%) |
|---|---|---|---|
| Divis Lab | 54.0 | 13.8 | 19% |
| Laurus Labs | 28.3 | 2.6 | 14.4% |
| ShilpaMedicare | 9.1 | 1.5 | 11.7% |
| AartiDrugs | 18.1 | 1.4 | 21.7% |
| Solara ActivePharma | 13.2 | 1.1 | 11.6% |
| Glenmark Life | 15.5 | 3.1 | 77.9% |
GLS is a leading developer and manufacturer of high value, non-commoditised APIs. Its portfolio comprises of 120 products (10 products in laboratory development; 4 products in laboratory validation and 106 products being commercialised) across various therapy areas like cardiovascular, CNS, diabetes, anti-infectives, and others.
The total market size in terms of sales for the 120 products globally, was estimated to be around US$140 bn in 2020 and is expected to grow by about 4.3% over the next five years to reach to about US$180 bn by 2026.
The future growth of these products is expected to remain stable driven by the rising prevalence of non-communicable diseases, growing demand from the regulated markets for drugs indicated for hypertension, diabetes and cancer, and ageing population.
Glenmark Life Sciences IPO grey market premium (GMP) today is Rs 120, which is around 17% higher from the issue price of the IPO, which has been fixed at Rs 695 to Rs 720.
The market mood seems positive in regard to the public issue.
According to the market observers, the GMP is an indication the market is expecting public issue listing at around 25-30% premium, which is expected to go further up once the issue opens for subscription.
In the past few months, a large number of corporate houses have submitted proposals for floating IPO. Besides this, a number of IPOs are expected to hit the market soon.
As companies line up to raise funds from the market amid high valuations, investors need to consider numerous factors before investing their money in an IPO.
If you are investing in an IPO, weigh in all the positive and negative factors affecting the company.
Take a close look at the company's financials and valuations. It would give you a clear picture of what's brewing.
Happy Investing!
Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...
CAPLIN POINT share price is trading up by 11% and its current market price is Rs 883. The BSE HEALTHCARE is up by 0.6%. The top gainers in the BSE HEALTHCARE Index is CAPLIN POINT (up 10.9%). The top losers are ABBOTT INDIA (down 0.1%) and ASTRAZENECA PHARMA (down 0.2%).
DIVIS LABORATORIES share price has hit an all time high at Rs 4,900 (up 1.5%). The BSE HEALTHCARE Index is up by 0.7%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 1.5%) and SANOFI INDIA (up 0.2%). The top losers include ALEMBIC PHARMA and BLISS GVS PHARMA .
CAPLIN POINT share price is trading up by 6% and its current market price is Rs 844. The BSE HEALTHCARE is up by 0.2%. The top gainers in the BSE HEALTHCARE Index is CAPLIN POINT (up 6.0%). The top losers are ERIS LIFESCIENCES (down 0.1%) and IPCA LABS (down 0.1%).
A look into the factors contributing to the rally in pharma stocks.
All you need to know about the IPO of Krishna Institute of Medical Sciences.
More Views on NewsAs an investor, you must have endeavoured to find a suitable opportunity for investing in IPOs. But do you know what is an IP...
Jul 13, 2021One technology company in India is grossly underrated despite its dominant role in semiconductor chip designing.
You now have a new way to create wealth. Grab it with both hands.
Why the global oil cartel is unravelling and how India stands to gain.
Jul 14, 2021A unique backdoor way of making big profits from smallcap companies.
Mor
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!